The Recurrent Fracture Trial enrolled patients post hip
fracture (mean age 74 ± 9.5 years; 55% > 75 years) and
the main outcomes reported in this mixed age cohort were
a reduction in new clinical fracture (35%; p = 0.001), new
clinical vertebral fracture (p = 0.002), non-vertebral fracture
(p = 0.03) but not hip fracture (p = 0.5). They also reported
an overall mortality benefit (RR 0.7; 95%CI 0.6–0.9; p =
0.01).